Patents by Inventor William J. Dower

William J. Dower has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200291067
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 17, 2020
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • Publication number: 20200291066
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 17, 2020
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • Patent number: 10703776
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 7, 2020
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • Patent number: 10689417
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: June 23, 2020
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • Publication number: 20200040034
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 6, 2020
    Applicant: MEDIKINE, INC.
    Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
  • Publication number: 20200040036
    Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 6, 2020
    Applicant: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • Publication number: 20180339043
    Abstract: Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.
    Type: Application
    Filed: May 24, 2018
    Publication date: November 29, 2018
    Inventors: David Campbell, Ramesh Bhatt, William J. Dower, Steven E. Cwirla, Blake M. Williams
  • Publication number: 20130012685
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 10, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Patent number: 8227422
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: July 24, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Publication number: 20120157660
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: June 21, 2012
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Patent number: 8202852
    Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: June 19, 2012
    Assignee: XenoPort, Inc.
    Inventors: Noa Zerangue, Qingzhi Gao, William J. Dower
  • Publication number: 20110282029
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: December 10, 2010
    Publication date: November 17, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Patent number: 7919454
    Abstract: The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: April 5, 2011
    Assignee: XenoPort, Inc.
    Inventors: Noa Zerangue, Tracy Dias, William J. Dower
  • Patent number: 7741062
    Abstract: Reagents and methods for detecting target proteins in a sample are provided. The reagents include a replicable genetic package, a protein displayed on an exterior surface of the package that is expressed from a heterologous nucleic acid borne by the package, and one or more antibodies complexed with the expressed protein and which have an open binding site for a target protein. Thus, a segment of the nucleic acid encodes for an epitope that is shared by the expressed polypeptide and the target protein. The reagents can be utilized individually or as part of a library or an array to bind target proteins within protein samples to form one or more complexes. By determining the sequence of the segment of the heterologous nucleic acid of a package within a complex, one can identify the target protein since the segment encodes for an epitope that is shared by the expressed and target proteins.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: June 22, 2010
    Assignee: XenoPort, Inc.
    Inventors: William J. Dower, Steven E. Cwirla
  • Publication number: 20100137255
    Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.
    Type: Application
    Filed: February 3, 2010
    Publication date: June 3, 2010
    Applicant: XenoPort, Inc.
    Inventors: Noa Zerangue, Qingzhi Gao, William J. Dower
  • Patent number: 7683043
    Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: March 23, 2010
    Assignee: XenoPort, Inc.
    Inventors: Noa Zerangue, Qingzhi Gao, William J. Dower
  • Publication number: 20090306036
    Abstract: The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter.
    Type: Application
    Filed: February 20, 2009
    Publication date: December 10, 2009
    Applicant: XenoPort, Inc.
    Inventors: Noa Zerangue, Tracy Dias, William J. Dower
  • Publication number: 20090280999
    Abstract: Reagents and methods for detecting target proteins in a sample are provided. The reagents include a replicable genetic package, a protein displayed on an exterior surface of the package that is expressed from a heterologous nucleic acid borne by the package, and one or more antibodies complexed with the expressed protein and which have an open binding site for a target protein. Thus, a segment of the nucleic acid encodes for an epitope that is shared by the expressed polypeptide and the target protein. The reagents can be utilized individually or as part of a library or an array to bind target proteins within protein samples to form one or more complexes. By determining the sequence of the segment of the heterologous nucleic acid of a package within a complex, one can identify the target protein since the segment encodes for an epitope that is shared by the expressed and target proteins.
    Type: Application
    Filed: April 7, 2009
    Publication date: November 12, 2009
    Applicant: XenoPort, Inc.
    Inventors: William J. Dower, Steven E. Cwirla
  • Publication number: 20090233808
    Abstract: Replicable genetic packages and collections thereof that display various compounds are provided. In some instances, the replicable genetic packages include nucleic acid tags that serve to record a characteristic of the compound or compounds that are attached to the replicable genetic package. The invention further provides a number of different methods for using the replicable genetic packages to screen a library of compounds for a desired biological activity.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 17, 2009
    Applicant: XenoPort, Inc.
    Inventors: Ronald W. Barrett, William J. Dower, Mark Gallop, Thomas F. Woiwode, Steven E. Cwirla
  • Publication number: 20090221442
    Abstract: A variety of methods for assaying libraries of test compounds as ligands and/or substrates of transport proteins, including both carrier-type and receptor-type transport proteins, are provided. Both in vitro and in vivo screening methods are disclosed. Also provided are methods for screening DNA libraries to identify members that encode transport proteins. Pharmaceutical compositions including compounds identified via the screening methods are also provided.
    Type: Application
    Filed: July 14, 2008
    Publication date: September 3, 2009
    Applicant: XenoPort, Inc.
    Inventors: William J. Dower, Mark Gallop, Ronald W. Barrett, Kenneth C. Cundy, Tania Chernov-Rogan